IDSI pursues NASDAQ listing
Breast imaging developer Imaging Diagnostic Systems of Plantation, FL, is trying to get listed on the NASDAQ stock exchange, but it has run into difficulty due to the stock exchange's listing requirements. One of NASDAQ's requirements is that IDSI
Breast imaging developer Imaging Diagnostic Systems of Plantation, FL, is trying to get listed on the NASDAQ stock exchange, but it has run into difficulty due to the stock exchange's listing requirements. One of NASDAQ's requirements is that IDSI execute a reverse stock split to bring the company's share prices above $4; however, IDSI's board determined that a reverse split would be detrimental to shareholders. IDSI reported that it would appeal the NASDAQ's requirements and continue to seek the listing.
In other IDSI news, the company announced that it has signed an agreement with Imation that enables IDSI to sell Imation's DryView laser printers with its CT Laser Mammography system, when CTLM becomes commercially available. IDSI will also begin to market DryView in the U.S. directly and internationally through its distributors. IDSI added a distributor in Turkey with the signing of an agreement with Emtron, which will have rights to market CTLM in the country for 18 months.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
